10-K - Immuneering Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Immuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024. The company generated no revenue, with total operating expenses of $59.4 million, primarily driven by $42.0 million in research and development and $17.3 million in general and administrative costs. The net loss per share was -$1.00. The company ended the year with a strong liquidity position, holding $217.0 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations into 2029. Key forward-looking activities include the planned initiation of the Phase 3 MAPKeeper 301 trial for its lead candidate atebimetinib in mid-2026.

Key Takeaways

1Reported a net loss of $56.0 million for FY 2025, an improvement from a $61.0 million loss in FY 2024.

2Holds $217.0 million in cash, cash equivalents, and marketable securities, funding operations into 2029.

3Incurred $59.4 million in total operating expenses, with $42.0 million dedicated to research and development.

4Plans to dose the first patient in the Phase 3 MAPKeeper 301 trial for atebimetinib in mid-2026.

5Has 53 full-time employees as of December 31, 2025, with 37 dedicated to research and development.

Key Financial Metrics

EPS

-$1.00

Not provided for prior year

Net Income

-$56.0M

+8.2%